Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
Adding Chemotherapy to Immune Therapy for Lung Cancer Shows Mixed Results
A meta-analysis of 3,252 patients reveals that adding chemotherapy to ICI monotherapy does not provide a consistent survival advantage.
New analysis suggests that adding chemotherapy to immunotherapy for certain lung cancers may not provide a consistent survival benefit over …
EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
Combination therapies show promise for lung cancer with brain spread
This systematic review and network meta-analysis of 5432 patients with EGFR-mutated non-small cell lung cancer and brain metastases found th…
New data suggests that combining specific drugs can improve survival and slow cancer growth in patients with lung cancer that has spread to …
Small bowel metastasis from esophageal squamous cell carcinoma shows male predominance and 6-month median survival
Small bowel spread from esophageal cancer has a short survival window
This systematic review of 23 patients with small bowel metastasis from esophageal squamous cell carcinoma found a strong male predominance (…
Patients with esophageal cancer that spreads to the small bowel often face a short survival window of about 6 months after diagnosis.
Perioperative immune checkpoint inhibitors with chemotherapy increase pathological complete response rate by 2.91 RR
Immune Checkpoint Inhibitors Combined With Chemotherapy Improve Cancer Response
This meta-analysis of randomized controlled trials evaluated perioperative immune checkpoint inhibitors combined with chemotherapy for resec…
Adding immune checkpoint inhibitors to chemotherapy may significantly improve response rates for patients with certain types of stomach and …
Traditional Chinese medicine injections combined with chemotherapy may improve outcomes and tolerability in advanced NSCLC
Traditional Chinese Medicine Injections May Improve Lung Cancer Treatment
This network meta-analysis of 6,386 patients evaluated various traditional Chinese medicine injections (TCMIs) added to chemotherapy for adv…
Combining certain traditional Chinese medicine injections with chemotherapy may improve treatment response and safety for patients with adva…
PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
Immunotherapy drugs increase rash risks for cancer patients
This meta-analysis evaluated the risk of developing rashes in cancer patients treated with PD-1 or PD-L1 inhibitors, both alone and in combi…
New data shows that certain immunotherapy drugs used to treat cancer significantly increase the risk of developing skin rashes.
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival
This meta-analysis of 3,910 patients with extensive-stage small-cell lung cancer (ES-SCLC) found that first-line immune checkpoint inhibitor…
Combining immune checkpoint inhibitors with chemotherapy shows better survival rates for patients with extensive stage small cell lung cance…
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
STR genotyping confirms gestational origin of pelvic choriocarcinoma, guiding risk score revision
Genetic testing helps identify the source of rare tumors
This case report describes a 29-year-old woman with pelvic gestational choriocarcinoma whose tumor origin was confirmed via STR genotyping, …
A 29-year-old woman with a rare tumor was treated successfully after genetic testing confirmed the exact origin of her cancer.
Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
Combination therapy shows mixed results for advanced prostate cancer
This meta-analysis evaluated the addition of PD-1 or PD-L1 inhibitors to chemotherapy for patients with metastatic castration-resistant pros…
Adding immunotherapy to chemotherapy for advanced prostate cancer may not improve survival for all patients and can lead to more severe side…
Chemotherapy plus traditional Chinese medicine improves progression-free survival in advanced non-small cell lung cancer
Traditional Chinese Medicine May Improve Survival in Lung Cancer
This systematic review and meta-analysis of individual patient data analyzed chemotherapy combined with traditional Chinese medicine (TCM) f…
Adding traditional Chinese medicine to chemotherapy may improve survival times for patients with advanced non-small cell lung cancer.
All chemotherapy Articles
- Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
- EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
- Small bowel metastasis from esophageal squamous cell carcinoma shows male predominance and 6-month median survival
- Perioperative immune checkpoint inhibitors with chemotherapy increase pathological complete response rate by 2.91 RR
- Traditional Chinese medicine injections combined with chemotherapy may improve outcomes and tolerability in advanced NSCLC
- PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patients
- Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
- First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer
- Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
- STR genotyping confirms gestational origin of pelvic choriocarcinoma, guiding risk score revision
- Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
- Chemotherapy plus traditional Chinese medicine improves progression-free survival in advanced non-small cell lung cancer
- Early postoperative chemotherapy reduces risk of death in patients with colorectal cancer
- Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinoma
- Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
- Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
- Surgical treatment and multimodal therapies characterize management options for rare penile melanoma cases
- PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
- Immune checkpoint inhibitor regimens for colorectal cancer increase risk of endocrine adverse events
- Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
- Pediatric Langerhans Cell Histiocytosis presents with skull involvement in 48.8% of cases
- Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
- Angiogenesis inhibitors combined with chemotherapy improve progression-free survival in advanced breast cancer patients
- Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
- PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
- Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
- Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
- Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
- Case report review highlights suspicion of breast cancer metastasis to thyroid in a 54-year-old woman
- Network meta-analysis suggests immune checkpoint inhibitor regimens improve survival in advanced gastric cancer compared to chemotherapy alone
- PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
- Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
- Network meta-analysis compares therapies for liver metastatic uveal melanoma
- Morning immune checkpoint inhibitor infusions associated with improved survival in metastatic non-small-cell lung cancer
- Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
- Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
- Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
- High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
- CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
- Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
- Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma
- Cadonilimab plus chemotherapy shows 72.5% ORR in 51 patients with cervical cancer
- Histology-derived gene-expression signatures predict distant recurrence-free interval and chemotherapy benefit in early breast cancer cohorts
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Review of combination strategies for digestive system tumors including gastric and colorectal cancer
- Breast cancer chemotherapy associated with taste alterations and dietary changes in Italian cohort
- Medicinal mushrooms may support immune function and tolerability in cancer patients receiving chemotherapy
- Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
- SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening
- Combining chemotherapy, immunotherapy, and high-dose radiation achieved remission in a patient with cervical esophageal adenocarcinoma
- Intravenous vitamin C did not reduce gastrointestinal toxicities but attenuated platelet decline in nasopharyngeal carcinoma patients
- Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles